DBV Technologies(US:DBVT) Globenewswire·2025-10-30 20:30Core Points - DBV Technologies has appointed Dr. Philina Lee as an independent director to its Board of Directors, effective October 30, 2025, replacing Daniel Soland, pending shareholder ratification [1][2] - Dr. Lee brings extensive experience in the biopharmaceutical sector, having previously served as Chief Commercial Officer at Blueprint Medicines, where she led the successful launch of AYVAKIT® [2] - The company is focused on advancing its proprietary VIASKIN® Peanut patch technology for treating peanut allergies in children and toddlers, with ongoing clinical trials [3][4] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in Warren, NJ, specializing in treatments for food allergies and other immunologic conditions [4] - The company is committed to transforming care for individuals with food allergies through its epicutaneous immunotherapy (EPIT) approach, which aims to desensitize the immune system to allergens [3]